Lymphocyte-predominant Hodgkin lymphoma (LPHL) was first described as Hodgkin’s paragranuloma by Jackson and Parker in 1944 [1]. Subsequently, a number of different terms such as lymphocytic-predominant Hodgkin’s disease or lymphocytic and histiocytic-predominant Hodgkin’s disease were used [2]. LPHL is rare, accounting for 5% of all Hodgkin lymphoma (HL) cases in western countries [3]. LPHL an...

Medical tourism emerged when people were challenged with high costs and slow service in medical care. As a consequence of these issues, people started to look for medical treatment in other countries. Globalization accelerated the growth of medical tourism. Several “push” and “pull” factors play roles in the motivation of patients to become a medical tourist. This review addresses the different...

Bendamustine has achieved widespread international regulatory approval and is a standard agent for the treatment for chronic lymphocytic leukemia (CLL), indolent non-Hodgkin lymphoma and multiple myeloma. Since approval, the number of indications for bendamustine has expanded to include aggressive non-Hodgkin lymphoma and Hodgkin lymphoma and novel targeted therapies, based on new bendamustine ...

We describe the case of a 13-year-old boy who presented with persistent thrombocytopenia during maintenance chemotherapy with mercaptopurine and methotrexate for T cell lymphoblastic lymphoma. He was diagnosed with immune thrombocytopenia (ITP) after thorough investigations for the relapse of lymphoma and was successfully treated with immunoglobulin and steroids. ITP is known to be associated w...

Malignant cells produce specific tumor antigen receptors (TAAs), which can be engineered to be recognized by a patient’s own T-cells through the expression of chimeric antigen receptors (CARs). These CAR-T cells represent the latest product of adoptive cellular immunotherapy (ACI). In particular, the engineering of CAR-T cells has been most successful to date in the targeting of CD-19 B-cell as...

Adoptive cellular immunotherapy (ACT) employing engineered T lymphocytes expressing chimeric antigen receptors (CARs) has demonstrated promising antitumor effects in advanced hematologic cancers, such as relapsed or refractory acute lymphoblastic leukemia, chronic lymphocytic leukemia, and non-Hodgkin lymphoma, supporting the translation of ACT to non-hematological malignancies. Although CAR T ...

If one accepts the established fact that the adrenal steroids have regulatory powers over nor mal lymphoid tissue, it would seem reasonable to assume that the adrenal steroids may also regulate the immature cells of lymphocytic leukemia. Since the advent of the clinical use of cortisone and of ÕCTH in April, 1949, many studies on both animals and human beings have been attempted to determine w...

Renal involvement in non-Hodgkin lymphoma, especially mantle cell lymphoma (MCL) is rare. A 77-year-old man presented with acute kidney injury (AKI), which rapidly progressed to dialysis dependence. Kidney biopsy revealed patchy B-cell lymphocytic aggregates in the interstitium, which were positive for cyclin D1, consistent with atypical CD5-negative MCL as confirmed by the detection of translo...

The FOXO transcription factors control proliferation and apoptosis in different cell types. Their activity is regulated by posttranslational modifications, mainly by the PI3K-PKB pathway, which controls nuclear export and degradation. We show that FOXO1 is highly expressed in normal germinal center B cells as well as in non-Hodgkin lymphomas, including follicular lymphoma, diffuse large B-cell ...

Non-Hodgkin lymphoma is a heterogeneous group of lympho-proliferative disorders. We performed a meta-analysis to summarize the available evidence from case-control studies and cohort study on the inconsistent association between occupational sun exposure and the risk of non-Hodgkin lymphoma. We searched PubMed, ISI web of science, the Cochrane Library, EMBASE and reference lists for relevant ar...